Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer

被引：222

作者：

An, Xin ^{[1
,2
]}

Ding, Pei-Rong ^{[1
,3
]}

Li, Yu-Hong ^{[1
,2
]}

Wang, Feng-Hua ^{[1
,2
]}

Shi, Yan-Xia ^{[1
,2
]}

Wang, Zhi-Qiang ^{[1
,2
]}

He, You-Jian ^{[1
,2
]}

Xu, Rui-Hua ^{[1
,2
]}

Jiang, Wen-Qi ^{[1
,2
]}

机构：

[1] State Key Lab Oncol S China, Guangzhou, Guangdong, Peoples R China

[2] Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China

[3] Sun Yat Sen Univ, Ctr Canc, Dept Colorectal Surg, Guangzhou 510275, Guangdong, Peoples R China

来源：

BIOMARKERS | 2010年 / 15卷 / 06期

关键词：

Chemotherapy; gemcitabine; neutrophil to lymphocyte ratio (NLR); pancreatic cancer; PHASE-III TRIAL; PREOPERATIVE NEUTROPHIL; GEMCITABINE; RESECTION; ADENOCARCINOMA; INFLAMMATION;

D O I：

10.3109/1354750X.2010.491557

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Background: Elevated neutrophil to lymphocyte ratio (NLR) is linked with worse survival in many malignancies, whereas its association with pancreatic cancer (PC) remains unclear. Methods: We retrospectively reviewed 95 patients with locally advanced or metastatic PC receiving gemcitabine-based chemotherapy. The prognostic value of NLR was evaluated. Results: Elevated pretreatment NLR (>5) was observed in 16 out of 89 eligible patients, which was identified as an independent prognostic factor for overall survival (OS). The median OS for patients with elevated and normal NLR were 2.4 months and 7.7 months, respectively (p < 0.001). Conclusions: Elevated NLR is a predictor of shorter survival in patients with advanced PC.

引用

页码：516 / 522

页数：7

共 22 条

[1]

An Xin, 2009, Ai Zheng, V28, P286

[2] Gemcitabine combined with oxaliplatin is safe and effective in patients with previously untreated advanced pancreatic adenocarcinoma [J].